Compare Vertex Pharmaceuticals Incorporated (VRTX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while YieldMax Universe Fund of Option Income ETFs trades at $7.49 (market cap $369.61M). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 346.7× YieldMax Universe Fund of Option Income ETFs's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| VRTX | YMAX | |
|---|---|---|
Market Cap | $128.16B | $369.61M |
Volume | 806,603 | 659,132 |
Sector | Health | Income / Options Overlay |
52-Week High | $557.96 | $12.98 |
52-Week Low | $407.37 | $7.27 |
Typical Hold Time | 120 Days | 55 Days |
Enterprise Value | $122.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a high distribution yield with weekly dividends, though recent coverage highlights concerns about NAV erosion and sustainability. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure, while support levels cluster around $7-8.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV performance. While the high yield attracts income investors, the fund faces risks from its fee structure and portfolio strategy. Analyst sentiment appears mixed with some highlighting yield benefits while others warn of principal erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
